ArticlePakistan journal of medical sciences2025
Clinical efficacy of low-intensity pulsed ultrasound plus hormone therapy in patients with postherpetic neuralgia: An observational study.
Article in Pakistan journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the clinical efficacy of low-intensity pulsed ultrasound (LIPUS) plus hormonal therapy in treating patients with postherpetic neuralgia (PHN). Method: This was an observational study. A total of 120 patients with diabetic peripheral neuropathic pain treated at Affiliated Hospital of Hebei University from May 2023 to May 2024 were selected and randomly divided into two groups. The control group received standard treatment, including maintaining the cleanliness and dryness of the rash, wearing loose clothing, local ultraviolet or infrared irradiation. The study group received LIPUS plus hormone therapy in addition to the standard treatment. Clinical outcomes, pain intensity, sleep quality and anxiety status before and after treatment were compared between the two groups. Results: The overall response rate was 88.33% in the study group and 70.00% in the control group, with the study group showing significantly higher efficacy (p= 0.013). There were no significant differences in VAS and PSQI scores between the two groups before treatment(p>0.05, respectively). After treatment, the study group exhibited more pronounced reductions in the VAS and PSQI scores compared to the control group, with statistically significant differences between the two groups (p< 0.05, respectively). There was no significant difference in the SAS score between the two groups before treatment (p= 0.556). Conclusion: LIPUS plus hormone therapy may provide significant clinical benefits in treating PHN, with marked improvements in pain relief, without increasing the risk of adverse reactions. Therefore, this combination therapy is considered safe and efficacious for patients with PHN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.